First GLP-1 Weight-Loss Pill Approved: What Foundayo (Orforglipron) Means for Tirzepatide Patients
Released: Last reviewed:
The FDA approved the first GLP-1 weight-loss pill. Here is what Foundayo delivers, what it costs, and how it stacks up against injectable and compounded tirzepatide.
By Dr. Parmis, Lead Medical Researcher · Medically reviewed by Adam Kennah, M.D. · Last reviewed July 9, 2026 · Sources cited at the end.
Direct answer
On April 1, 2026, the FDA approved Foundayo (orforglipron), the first small-molecule GLP-1 pill for chronic weight management. In the ATTAIN-1 trial the highest dose produced roughly 11–12% average body-weight loss at 72 weeks. It is a once-daily tablet — no needles — and, unlike the older oral GLP-1 Rybelsus, can be taken any time with or without food or water. Injectable tirzepatide still tends to produce greater average loss, but the pill adds an FDA-approved, needle-free option to the market.
Why this is a milestone
Every GLP-1 obesity medicine before Foundayo required an injection or (for Rybelsus, a diabetes-only pill) strict fasting rules. A convenient daily tablet lowers two real barriers: needle aversion and dosing friction. Orforglipron was discovered by Chugai and licensed by Lilly, and is also being studied for type 2 diabetes and other conditions.
How it compares with injectable tirzepatide
| Feature | Foundayo (orforglipron) | Injectable tirzepatide |
|---|---|---|
| Form | Once-daily oral tablet | Weekly injection |
| Molecule | Single GLP-1 (non-peptide) | Dual GIP/GLP-1 (peptide) |
| FDA status | Approved Apr 1, 2026 | Approved (Mounjaro/Zepbound) |
| Avg weight loss | ~11–12% (ATTAIN-1, top dose) | ~15–21% by dose (SURMOUNT-1) |
| Advertised cost | $25/mo insured; $149 self-pay | Varies; brand and compounded differ |
What the weight-loss data show
Market impact
Telehealth moved quickly: Ro signed a deal with Lilly in April 2026 to offer Foundayo alongside its existing programs, and other platforms signaled plans to add it. The approval does not change the status of compounded tirzepatide, which remains a separate, non-FDA-approved category. For a patient-facing walkthrough, see our oral pill vs compounded tirzepatide comparison.
Who might prefer a pill
A daily tablet meaningfully lowers two barriers that keep people off injectables: needle aversion and the logistics of weekly shots. For patients who have delayed treatment for those reasons, an FDA-approved oral option is genuinely new. The trade-off is a daily habit and somewhat lower average weight loss than injectable tirzepatide — a reasonable exchange for many, less so for those seeking the largest possible result.
What we still do not know
Foundayo is new, so long-term real-world data are still accumulating. Its cardiovascular-outcomes profile, durability of weight loss beyond the trial window, and performance against injectable tirzepatide in a true head-to-head are open questions. Orforglipron is also being studied in type 2 diabetes and other conditions, so its approved uses may expand. As with any GLP-1, gastrointestinal side effects are common early on. Anyone considering it should review personal history and cost with a clinician rather than assuming the newest option is automatically the best fit.
Frequently asked questions
What is Foundayo? Foundayo (orforglipron) is the first FDA-approved oral GLP-1 pill for chronic weight management, approved April 1, 2026. It is a once-daily tablet taken any time, with or without food.
Is Foundayo the same as tirzepatide? No. Foundayo is a single GLP-1 receptor agonist and a non-peptide small molecule; tirzepatide is an injectable dual GIP/GLP-1 agonist. They are different medicines.
How much weight did people lose? In ATTAIN-1, the highest dose produced roughly 11–12% average body-weight loss at 72 weeks (about 27 pounds among those who stayed on treatment), versus about 2% on placebo.
What does it cost? Lilly advertises Foundayo via LillyDirect at about $25/month with commercial coverage and $149/month for self-pay, expanding into retail and telehealth.
July 9, 2026: Published; approval, trial figures, and pricing verified against Lilly and FDA sources.
April 1, 2026: FDA approved Foundayo (orforglipron).
Sources
- Eli Lilly — FDA approves Foundayo (orforglipron) — April 1, 2026
- Drugs.com — Foundayo (orforglipron) approval history
- Patient Care Online — FDA approves orforglipron, first oral GLP-1 for weight loss
Important: Compounded tirzepatide is not FDA-approved and is not the same medicine as Mounjaro or Zepbound, the only FDA-approved tirzepatide products (Eli Lilly and Company). This page is educational and is not medical or legal advice. Weight-loss medications require evaluation and, when appropriate, a prescription from a licensed clinician. Individual results and side effects vary. Confirm current FDA status, pricing, and clinical guidance directly before acting.